ArticleBMC cardiovascular disorders2025
Analysis of risk factors for adverse events associated with cardiogenic syncope due to coronary artery disease in the elderly.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo analyze risk factors for adverse events associated with syncope due to coronary artery disease (CAD) in the elderly.
methodsTwo hundred eight patients with CAD who were hospitalized for cardiogenic syncope in our hospital from September 2022 to September 2023 were included in this study. Based on the follow-up results, 208 patients with cardiogenic syncope due to geriatric coronary artery disease were classified into the no-adverse group (n = 171), and the adverse group (n = 37), and the risk factors for the occurrence of adverse events in cardiogenic syncope in both groups were analyzed.
resultsThe age differences, history of heart failure, cardiac troponin I (hs-TnT) level, N-terminal B-type natriuretic peptide proteins (NT-proBNP) level, heart rate, left ventricular ejection fraction (LVEF), and QTC abnormality between the two groups were statistically significant (P < 0.05). The COX multifactorial regression analysis revealed that hs-TnT, NT-proBNP, QTC abnormality prolongation and LVEF were all identified as risk factors for poor prognosis in elderly CAD patients (P < 0.05). proBNP, abnormal prolongation of QTC, and LVEF were identified as risk factors for cardiogenic syncope in elderly CAD patients, leading to a poor prognosis (P < 0.05). ROC curve analysis demonstrated that combining hs-TnT, NT-proBNP, QTC, and LVEF tests resulted in higher diagnostic accuracy than a single test alone, significantly improving the diagnostic accuracy (P < 0.05).
conclusionHigh hs-TnT and NT-proBNP levels, abnormally prolonged QTC, and LVEF > 50% are risk factors for cardiogenic syncope leading to adverse events in elderly CAD patients. The clinical Trial Number of this study is CLTR202356423, and it was registered in 2023.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.